Skip to main content

Table 2 Cancer risks (incidence rate ratios RR) in men with residence in communities with a large or medium area under wine cultivation vs. men in communities with low area under wine cultivation

From: Cancer risk among residents of Rhineland-Palatinate winegrowing communities: a cancer-registry based ecological study

 

Reference* (1,665,594 PY†)

Area under wine cultivation > 5, ≤ 20% of community area (1,039,435 PY†)

Area under wine cultivation > 20% of community area (612,714 PY†)

ICD-10 code

Cases

Cases

RR‡§

95% CI

Cases

RR‡§

95% CI

Head & neck (C00–C14)

369

188

0.91

0.72–1.15

94

0.86

0.65–1.14

Base of tongue (C01)

35

11

0.53

0.26–1.08

10

0.87

0.40–1.91

Other and unspecified parts of tongue (C02)

35

26

1.22

0.72–2.07

13

1.12

0.56–2.25

Floor of mouth (C04)

42

25

0.98

0.57–1.70

11

0.70

0.34–1.47

Palate (C05)

22

15

1.24

0.62–2.49

5

0.88

0.31–2.54

Other and unspecified parts of mouth (C06)

18

8

0.71

0.29–1.73

3

0.45

0.12–1.71

Parotid gland (C07)

14

8

0.92

0.36–2.30

4

0.80

0.24–2.67

Tonsil (C09)

47

22

0.78

0.45–1.34

13

0.79

0.40–1.56

Oropharynx (C10)

35

15

0.78

0.39–1.57

5

0.48

0.17–1.34

Piriform sinus (C12)

20

10

0.90

0.41–2.02

8

1.67

0.66–4.25

Hypopharynx (C13)

56

27

0.76

0.46–1.26

17

0.88

0.48–1.62

Oesophagus (C15)

156

94

0.96

0.73–1.27

42

0.82

0.57–1.20

Stomach (C16)

241

166

1.06

0.86–1.31

92

1.03

0.79–1.34

Small intestine (C17)

24

14

0.92

0.45–1.86

2

0.21

0.05–0.95

Colon, sigmoid & rectum (C18–C21)

1188

806

1.07

0.95–1.21

460

1.10

0.96–1.26

Colon (C18)

723

473

1.04

0.91–1.20

268

1.06

0.90–1.25

Rectosigmoid junction (C19)

51

42

1.33

0.89–2.00

30

1.68

1.04–2.71

Rectum (C20)

397

284

1.13

0.94–1.35

157

1.10

0.89–1.37

Anus and anal canal (C21)

17

7

0.66

0.26–1.64

5

0.85

0.29–2.50

Liver and intrahepatic bile ducts (C22)

141

73

0.94

0.68–1.30

37

0.88

0.58–1.32

Gallbladder & biliary tract (C23–C24)

76

33

0.67

0.44–1.02

27

0.95

0.59–1.54

Gallbladder (C23)

17

7

0.58

0.23–1.46

7

0.96

0.36–2.53

Other and unspecified parts of biliary tract (C24)

59

26

0.70

0.43–1.13

20

0.95

0.55–1.65

Pancreas (C25)

162

99

1.03

0.78–1.36

51

0.96

0.68–1.37

Nasal cavity and middle ear (C30–C31)

18

9

0.73

0.32–1.67

4

0.51

0.16–1.62

Larynx (C32)

135

78

0.94

0.68–1.29

39

0.88

0.59–1.31

Trachea, bronus and lung (C33–C34)

1039

530

0.98

0.84–1.14

232

0.77

0.64–0.92

Bronchus and lung (C34)

1036

530

0.98

0.84–1.15

232

0.77

0.64–0.92

Bone and articular cartilage (C40–C41)

11

7

0.88

0.32–2.42

3

0.49

0.13–1.89

Skin, malignant melanoma (C43)

230

188

1.32

1.08–1.60

119

1.50

1.18–1.91

Skin, other malignant neoplasms (C44)

1990

1748

1.32

1.20–1.45

959

1.39

1.25–1.54

Mesothelioma (C45)

19

12

1.09

0.52–2.28

5

0.92

0.32–2.68

Other connective and soft tissue (C49)

32

35

1.65

1.00–2.70

9

0.68

0.31–1.48

Breast (C50)

14

9

1.02

0.43–2.39

3

0.60

0.16–2.25

Penis (C60)

20

15

1.17

0.56–2.44

6

0.71

0.26–1.93

Prostate (C61)

1857

1359

1.26

1.12–1.41

787

1.26

1.11–1.43

Testis (C62)

154

107

1.18

0.88–1.60

77

1.31

0.94–1.83

Urinary tract (C64-C66+C68)

330

206

1.03

0.85–1.26

107

0.96

0.75–1.23

Kidney, except renal pelvis (C64)

269

171

1.06

0.86–1.32

89

1.00

0.76–1.31

Ureter (C66)

30

7

0.35

0.15–0.80

7

0.58

0.24–1.39

Bladder (C67, D09.0, D41.4)

699

470

1.16

1.01–1.34

266

1.31

1.10–1.55

Eye and adnexa (C69)

15

8

1.02

0.43–2.43

3

0.88

0.23–3.37

Meninges (C70)

22

20

1.45

0.78–2.69

7

0.88

0.35–2.18

Brain, CNS, meninges (C70–C72, D32–33, D42–43)

133

90

1.08

0.81–1.44

53

1.04

0.73–1.49

Brain (C71, D33, D43)

109

70

1.02

0.74–1.41

45

1.06

0.72–1.57

Thyroid gland (C73)

33

23

1.11

0.64–1.92

16

1.31

0.68–2.53

Hodgkin's disease (C81)

40

24

0.86

0.51–1.46

12

0.64

0.32–1.27

Follicular NHL (C82)

29

21

1.23

0.67–2.25

19

1.98

1.01–3.85

NHL (C82–C85)

197

130

1.12

0.88–1.42

81

1.29

0.96–1.73

Diffuse NHL (C83)

122

66

0.91

0.66–1.24

31

0.80

0.52–1.23

Peripheral and cutaneous T-cell lymphomas (C84)

10

6

0.94

0.33–2.68

8

2.19

0.75–6.37

Other and unspecified types of NHL (C85)

36

37

1.64

1.03–2.59

23

1.84

1.05–3.23

Multiple myeloma (C90)

63

36

0.93

0.60–1.44

21

0.92

0.53–1.59

Leukaemia (C91–C95)

204

113

0.89

0.69–1.15

61

0.84

0.61–1.16

Lymphoid leukaemia (C91)

116

56

0.74

0.53–1.05

28

0.65

0.41–1.02

Myeloid leukaemia (C92)

77

52

1.09

0.75–1.59

27

0.99

0.61–1.60

Primary site unspecified

128

83

0.99

0.75–1.30

43

0.88

0.61–1.28

All malignancies (excluding C44)

7761

5024

1.12

1.05–1.19

2765

1.10

1.03–1.18

All malignancies (including C44)

9751

6772

1.15

1.09–1.22

3724

1.16

1.09–1.23

  1. * Winegrowing communities with >0, <= 5% area under wine cultivation
  2. † PY: Person-Years were approximated by population figures: the sum of population at the end of the year in the years under consideration.
  3. ‡ adjusted for age, rural or urban environment, and fruit cultivation
  4. § Poisson distribution of case counts assumed for: C45, C50, C70
Back to article page

Journal of Occupational Medicine and Toxicology

ISSN: 1745-6673